ArticleMetabolomics : Official journal of the Metabolomic Society2026
Plasma metabolomic signatures of all and cause-specific cancers: a multi-platform population-based study.
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolomic Insights into Head and Neck Cancer: Recent Advances and Future Directions.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionEarly diagnosis of cancer is essential for improving patient outcomes. Metabolomics analysis has shown promise in detecting cancer and distinguishing its metastatic burdens in previous studies.
objectivesWe hypothesized that metabolomics data can differentiate between people with and without cancer at a population level, uncovering new biomarkers and deepening our understanding of cancer metabolism.
methodsA total of 1,386 metabolites were measured by two commonly used metabolomics platforms: Nightingale and Metabolon, in baseline plasma samples from participants in the population-based Rotterdam Study, with sample sizes of 2,538 and 5,057, respectively. Logistic regression and competing risk Cox proportional hazards models were employed to examine associations between these metabolites and both baseline prevalent and incident during follow-up of all and cause-specific cancers. Statistical significance was defined by a false discovery rate (FDR) < 0.05.
resultsThere were 654 cancer cases at baseline, and 618 new cases also occurred during follow-up of nearly 10 years. In the cross-sectional study, 68, 7, and 10 metabolites were significantly associated with prevalent blood, colorectal, and all cancer, after multivariate adjustment. In the longitudinal study, 19, 11, 2, 3, and 1 metabolites were significantly associated with incident blood, colorectal, lung, prostate, and all cancer, respectively. Among these, 17 and 2 metabolites were associated with both prevalent and incident blood and colorectal cancer.
conclusionsThis study indicates several circulating metabolites that are associated with different cancers. These metabolites may contribute to better understanding of the metabolic pathways of cancer and serve as biomarkers for early cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.